Skip To Main Content
For US Healthcare Professionals
yellow swoosh

OCREVUS Pricing and Financial Support

Having MS can come with many challenges. We believe that getting your medicine shouldn't be one of them. We have programs to help you pay for the treatment your doctor prescribed.

On this page, you’ll find information about:

  • The list price of OCREVUS
  • What you might expect to pay
  • Financial support programs that may be available to you

What could I expect to pay?

The current list price of OCREVUS is $68,121.64 annually, but most people will not pay this amount. The amount you pay for OCREVUS depends on a variety of factors, including your insurance coverage.

Below, you can learn more about how we may be able to help you pay for OCREVUS.

What type of insurance do you have?

There is a wide range of insurance plans, and each individual’s out-of-pocket cost differs based on the insurance plan. Therefore, the best way to understand your out-of-pocket cost for OCREVUS is to contact your insurance provider.

If you have commercial or private insurance, you may be eligible for OCREVUS Co-Pay assistance. Patients who used the OCREVUS Co-pay Card pay as little as $10 per treatment and up to $15 for a full year of OCREVUS.*

There may be additional costs related to the administration of OCREVUS and other medications you may take as part of the infusion. These will vary depending on your healthcare provider and/or location of the infusion. Please contact your plan provider for the most accurate cost estimate.

*Data from 2021.

Your cost for a year of OCREVUS may range between $0 and $14,000. About half of patients pay $0.

Your expenses may vary depending on your Medicare plan benefits, healthcare provider and location of OCREVUS administration. If you have Medicare Part B and supplemental insurance, most or all of your OCREVUS costs will be covered by the plan. If you have Medicare Advantage, plan designs and out-of-pocket expenses may vary depending on your other healthcare expenses and whether you have hit your out-of-pocket maximum. Please check with your plan provider for more details.

If you are unable to afford OCREVUS, you may be eligible for additional assistance through the Genentech Patient Foundation. Learn more here.

Your cost for a year of OCREVUS will likely be nominal. The specific amount will vary depending on your income level and state regulations.

For more information about the Medicaid plan for your state, please visit the Medicaid website.

If you do not have insurance and/or cannot afford OCREVUS, we may be able to help. You may be eligible for additional assistance through the Genentech Patient Foundation. Learn more.

We are committed to helping you.

You are not alone. If you have any questions regarding OCREVUS and MS, call 1-844-OCREVUS. We will walk through each step of the treatment journey with you.

Once you have been prescribed OCREVUS, you will receive personalized support from a Patient Navigator who will help you understand your options and how you might obtain financial assistance.

OCREVUS® (ocrelizumab) copay card icon

The OCREVUS Co-pay Program*

The OCREVUS Co-pay Program helps people with commercial health insurance. This might be a plan you get through your employer or one you purchased through a Health Insurance Marketplace like HealthCare.gov. To qualify, you must also meet other criteria.

Learn More
OCREVUS® (ocrelizumab) pricing access solutions icon

Independent Co-pay Assistance Foundations†

If you need help with your co-pay for your Genentech medicine, OCREVUS Access Solutions can refer you to an independent co-pay assistance foundation. Independent co-pay assistance foundations help patients with public health insurance or commercial health insurance.

Learn More
OCREVUS® (ocrelizumab) patient foundation icon

Genentech Patient Foundation‡

The Genentech Patient Foundation gives free OCREVUS to people who don’t have insurance coverage or who have financial concerns.

Learn More

*In order to be eligible for the OCREVUS Co-pay Card, the patient must have commercial insurance; must not have Medicare, Medicaid or other government insurance; and must meet other eligibility criteria. They also must agree to the rules set forth in the terms and conditions for the program. Please visit www.OCREVUS.com/copay for the full list of terms and conditions.

†Independent Co-pay assistance foundations have their own rules for eligibility. We cannot guarantee a foundation will help you. We only refer you to a foundation that supports your disease state. We do not endorse or show financial preference for any particular foundation. The foundations we refer you to are not the only ones that might be able to help you.

‡If you have health insurance for your medicine, you must have already tried other types of patient assistance to qualify for free OCREVUS from the Genentech Patient Foundation. This includes the OCREVUS Co-pay Card and support from independent co-pay assistance foundations. You must also meet financial criteria. If you do not have insurance or your insurance does not cover your medicine, you must meet different financial criteria.

What is OCREVUS?

OCREVUS is a prescription medicine used to treat:

  • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
  • Primary progressive MS, in adults.

It is not known if OCREVUS is safe and effective in children.

Who should not receive OCREVUS?

Do not receive OCREVUS if you have an active hepatitis B virus (HBV) infection.

Do not receive OCREVUS if you have had a life-threatening allergic reaction to OCREVUS. Tell your healthcare provider if you have had an allergic reaction to OCREVUS or any of its ingredients in the past.

What is the most important information I should know about OCREVUS?

OCREVUS can cause serious side effects, including:

  • Infusion reactions: Infusion reactions are a common side effect of OCREVUS, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infusion reaction. Tell your healthcare provider or nurse if you get any of these symptoms:
    • itchy skin
    • rash
    • hives
    • tiredness
    • coughing or wheezing
    • trouble breathing
    • throat irritation or pain
    • feeling faint
    • fever
    • redness on your face (flushing)
    • nausea
    • headache
    • swelling of the throat
    • dizziness
    • shortness of breath
    • fatigue
    • fast heart beat

These infusion reactions can happen for up to 24 hours after your infusion. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion. If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.

  • Infection:
    • OCREVUS increases your risk of getting upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes infections. Infections are a common side effect, which can be serious. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, or a cough that does not go away. Signs of herpes include cold sores, shingles, genital sores, skin rash, pain, and itching. Signs of more serious herpes infection include: changes in vision, eye redness or eye pain, severe or persistent headache, stiff neck, and confusion. Signs of infection can happen during treatment or after you have received your last dose of OCREVUS. Tell your healthcare provider right away if you have an infection. Your healthcare provider should delay your treatment with OCREVUS until your infection is gone.
    • Progressive Multifocal Leukoencephalopathy (PML): Although no cases have been seen with OCREVUS treatment in clinical trials, PML may happen with OCREVUS. PML is a rare brain infection that usually leads to death or severe disability.  Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms. These may include problems with thinking, balance, eyesight, weakness on 1 side of your body, strength, or using your arms or legs.
    • Hepatitis B virus (HBV) reactivation: Before starting treatment with OCREVUS, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with OCREVUS. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving OCREVUS.
    • Weakened immune system: OCREVUS taken before or after other medicines that weaken the immune system could increase your risk of getting infections.
  • Decreased immunoglobulins: OCREVUS may cause a decrease in some types of immunoglobulins. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.

Before receiving OCREVUS, tell your healthcare provider about all of your medical conditions, including if you:

  • have ever taken, take, or plan to take medicines that affect your immune system, or other treatments for MS.
  • have ever had hepatitis B or are a carrier of the hepatitis B virus.
  • have had a recent vaccination or are scheduled to receive any vaccinations. 
    • You should receive any required ‘live’ or ‘live-attenuated’ vaccines at least 4 weeks before you start treatment with OCREVUS. You should not receive ‘live’ or ‘live attenuated’ vaccines while you are being treated with OCREVUS and until your healthcare provider tells you that your immune system is no longer weakened.
    • When possible, you should receive any ‘non-live’ vaccines at least 2 weeks before you start treatment with OCREVUS. If you would like to receive any non-live (inactivated) vaccines, including the seasonal flu vaccine, while you are being treated with OCREVUS, talk to your healthcare provider.
    • If you have a baby and you received OCREVUS during your pregnancy, it is important to tell your baby’s healthcare provider about receiving OCREVUS so they can decide when your baby should be vaccinated.
  • are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if OCREVUS will harm your unborn baby. You should use birth control (contraception) during treatment with OCREVUS and for 6 months after your last infusion of OCREVUS. Talk with your healthcare provider about what birth control method is right for you during this time.
    • Pregnancy Registry. There is a pregnancy registry for women who take OCREVUS during pregnancy. If you become pregnant while receiving OCREVUS, tell your healthcare provider right away. Talk to your healthcare provider about registering with the OCREVUS Pregnancy Registry. The purpose of this registry is to collect information about your health and your baby’s health. Your healthcare provider can enroll you in this registry by calling 1-833-872-4370 or visiting www.ocrevuspregnancyregistry.com.
  • are breastfeeding or plan to breastfeed. It is not known if OCREVUS passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take OCREVUS.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of OCREVUS?

OCREVUS may cause serious side effects, including:

  • Risk of cancers (malignancies) including breast cancer. Follow your healthcare provider’s instructions about standard screening guidelines for breast cancer.

These are not all the possible side effects of OCREVUS.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

For more information, go to www.OCREVUS.com or call 1-844-627-3887.

For additional safety information, please see the full Prescribing Information and Medication Guide.

    • OCREVUS Prescribing Information. Genentech, Inc. 2016.

      OCREVUS Prescribing Information. Genentech, Inc. 2016.